|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
183,678,000 |
Market
Cap: |
5.01(B) |
Last
Volume: |
775,760 |
Avg
Vol: |
773,548 |
52
Week Range: |
$23.37 - $33.63 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 581 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
35,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
15,666 |
15,666 |
89,488 |
296,961 |
Total Sell Value |
$454,291 |
$454,291 |
$2,700,159 |
$8,679,342 |
Total People Sold |
3 |
3 |
4 |
7 |
Total Sell Transactions |
3 |
3 |
7 |
17 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-03-18 |
4 |
AS |
$28.10 |
$292,740 |
D/D |
(10,417) |
65,911 |
|
-1% |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-27 |
4 |
S |
$29.65 |
$75,874 |
D/D |
(2,559) |
7,717 |
|
10% |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-23 |
4 |
D |
$29.57 |
$84,127 |
D/D |
(2,845) |
76,328 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,407 |
79,173 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-23 |
4 |
D |
$29.57 |
$19,871 |
D/D |
(672) |
10,276 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,283 |
10,948 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-23 |
4 |
D |
$29.57 |
$114,732 |
D/D |
(3,880) |
157,802 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,737 |
161,682 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-23 |
4 |
D |
$29.57 |
$100,952 |
D/D |
(3,414) |
164,782 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,689 |
168,196 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-23 |
4 |
D |
$29.57 |
$53,551 |
D/D |
(1,811) |
281,730 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,077 |
283,541 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-23 |
4 |
D |
$29.57 |
$76,498 |
D/D |
(2,587) |
116,344 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,825 |
118,931 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-23 |
4 |
D |
$29.57 |
$100,952 |
D/D |
(3,414) |
109,709 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,689 |
113,123 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-22 |
4 |
D |
$28.91 |
$157,617 |
D/D |
(5,452) |
105,434 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,278 |
110,886 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-22 |
4 |
D |
$28.91 |
$95,403 |
D/D |
(3,300) |
160,507 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,431 |
163,807 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-22 |
4 |
D |
$28.91 |
$91,240 |
D/D |
(3,156) |
113,106 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,108 |
116,262 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-22 |
4 |
D |
$28.91 |
$55,767 |
D/D |
(1,929) |
279,464 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,654 |
281,393 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-22 |
4 |
D |
$28.91 |
$124,429 |
D/D |
(4,304) |
152,945 |
|
- |
|
2018 Records found
|
|
Page 1 of 81 |
|
|